<DOC>
	<DOCNO>NCT02946931</DOCNO>
	<brief_summary>To evaluate safety effectiveness Prizbind® Intravenous Solution 2.5 g Japanese clinical condition</brief_summary>
	<brief_title>PMS Idarucizumab Japan</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Inclusion criterion : Patients prescribe Prizbind® Intravenous Solution 2.5 g discretion investigator Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>